Checkpoint inhibitor immunotherapy during pregnancy for relapsed-refractory Hodgkin lymphoma.

Evens, Andrew M; Brandt, Justin S; Peer, Cody J; Yin, Tyler; Schaar, Dale; Farooq, Faheem; Mozarsky, Brett; Figg, William D; Sharon, Elad

Evens, Andrew M; Brandt, Justin S; Peer, Cody J; Yin, Tyler; Schaar, Dale; Farooq, Faheem; Mozarsky, Brett; Figg, William D; Sharon, Elad.

Afiliação

Evens AM; Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
Brandt JS; Departments of Medicine and Maternal Fetal Medicine, Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA.
Peer CJ; Departments of Medicine and Maternal Fetal Medicine, Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA.
Yin T; Clinical Pharmacology Program, National Cancer Institute, Bethesda, Maryland, USA.
Schaar D; Clinical Pharmacology Program, National Cancer Institute, Bethesda, Maryland, USA.
Farooq F; Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
Mozarsky B; Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
Figg WD; Clinical Pharmacology Program, National Cancer Institute, Bethesda, Maryland, USA.
Sharon E; Clinical Pharmacology Program, National Cancer Institute, Bethesda, Maryland, USA.

Am J Hematol ; 97(6): 833-838, 2022 06 01.

Article em En | MEDLINE | ID: mdl-35285979

Assuntos

Doença de Hodgkin; Feminino; Doença de Hodgkin/tratamento farmacológico; Doença de Hodgkin/patologia; Humanos; Fatores Imunológicos; Imunoterapia; Gravidez

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Hodgkin Limite: Female / Humans / Pregnancy Idioma: En Revista: Am J Hematol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google